New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron

Journal of Toxicological Sciences

Volumn 39, Issue 1, 2014, Pages 1-6

  Kaizaki, Asuka ^a   Tanaka, Sachiko ^a   Numazawa, Satoshi ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

1 phenyl 2 (1 pyrrolidinyl) 1 pentanone ( PVP); Dopamine neuron; Locomotor activity; Methamphetamine (METH)

Indexed keywords

1 PHENYL 2 (1 PYRROLIDINYL) 1 PENTANONE; CATHINONE; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; METHAMPHETAMINE; SCH 23990; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; HYPERACTIVITY; LETTER; LOCOMOTION; MALE; MICRODIALYSIS; MOUSE; NEUROTOXICITY; NONHUMAN;

ANIMALS; BENZAZEPINES; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DESIGNER DRUGS; DOPAMINE; DOPAMINERGIC NEURONS; MALE; METHAMPHETAMINE; MICE; MOTOR ACTIVITY; PENTANONES; PYRROLIDINES; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SULPIRIDE;

EID: 84891892940     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.39.1     Document Type: Letter

References (23)

1. Angoa-Pérez, M., Kane, M.J., Francescutti, D.M., Sykes, K.E., Shah, M.M., Mohammed, A.M., Thomas, D.M. and Kuhn, D.M. (2012): Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J. Neurochem., 120, 1097-1107.
2. Brandt, S.D., Sumnall, H.R., Measham, F. and Cole, J. (2010): Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal., 2, 377-382.
3. Callahan, J.W. and Abercrombie, E.D. (2011): In vivo dopamine efflux is decreased in striatum of both fragment (R6/2) and fulllength (YAC128) transgenic mouse models of Huntington's disease. Front Syst. Neurosci., 5, 61.
4. Carroll, F.I., Blough, B.E., Mascarella, S.W., Navarro, H.A., Eaton, J.B., Lukas, R.J. and Damaj, M.I. (2010): Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J. Med. Chem., 53, 2204-2214.
5. Cozzi, N.V., Sievert, M.K., Shulgin, A.T., Jacob, P. and Ruoho, A.E. (1999): Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur. J. Pharmacol., 381, 63-69.
6. Damaj, M.I., Carroll, F.I., Eaton, J.B., Navarro, H.A., Blough, B.E., Mirza, S., Lukas, R.J. and Martin, B.R. (2004): Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol., 66, 675-682.
7. den Hollander, B., Rozov, S., Linden, A.M., Uusi-Oukari, M., Ojanperä, I. and Korpi, E.R. (2013): Long-term cognitive and neurochemical effects of "bath salt" designer drugs methylone and mephedrone. Pharmacol. Biochem. Behav., 103, 501-509.
8. Fleckenstein, A.E., Gibb, J.W. and Hanson, G.R. (2000): Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol., 406, 1-13.
9. Glennon, R.A., Yousif, M., Naiman, N. and Kalix, P. (1987): Methcathinone: a new and potent amphetamine-like agent. Pharmacol. Biochem. Behav., 26, 547-551.
10. James, D., Adams, R.D., Spears, R., Cooper, G., Lupton, D.J., Thompson, J.P. and Thomas, S.H. (2011): National Poisons Information Service. Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emerg. Med. J., 28, 686-689.
11. Kalix, P. (1992): Cathinone, a natural amphetamine. Pharmacol. Toxicol., 70, 77-86.
12. Marinetti, L.J. and Antonides, H.M. (2013): Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J. Anal. Toxicol., 37, 135-146.
13. Marusich, J.A., Grant, K.R., Blough, B.E. and Wiley, J.L. (2012): Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice. Neurotoxicology, 33, 1305-1313.
14. Meltzer, P.C., Butler, D., Deschamps, J.R. and Madras, B.K. (2006): 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem., 49, 1420-1432.
15. Numazawa, S. (2013): The forefront of drug abuse-Recent trends in illegal drugmarkets in Japan, 2012-. Showa Univ. J. Pharmaceut. Sci., 4, 13-25.
16. Pierce, R.C. and Kalivas, P.W. (1997): A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Brain Res. Rev., 25, 192-216.
17. Rothman, R.B., Baumann, M.H., Dersch, C.M., Romero, D.V., Rice, K.C., Carroll, F.I. and Partilla, J.S. (2001): Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 39, 32-41.
18. Sauer, C., Peters, F.T., Haas, C., Meyer, M.R., Fritschi, G. and Maurer, H.H. (2009): New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass. Spectrom., 44, 952-964.
19. Vazquez, J.F., Clement, H.W., Sommer, O., Schulz, E. and van Calker, D. (2008): Local stimulation of the adenosine A2B receptors induces an increased release of IL-6 in mouse striatum: an in vivo microdialysis study. J. Neurochem., 105, 904-909.
20. White, F.J. and Kalivas, P.W. (1998): Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend., 51, 141-153.
21. Widler, P., Mathys, K., Brenneisen, R., Kalix, P. and Fisch, H.U. (1994): Pharmacodynamics and pharmacokinetics of khat: a controlled study. Clin. Pharmacol. Ther., 55, 556-562.
22. Winstock, A.R., Mitcheson, L.R., Deluca, P., Davey, Z., Corazza, O. and Schifano, F. (2011): Mephedrone, new kid for the chop? Addiction., 106, 154-161.
23. Zhang, L., Kitaichi, K., Fujimoto, Y., Nakayama, H., Shimizu, E., Iyo, M. and Hashimoto, K. (2006): Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog. Neuropsychopharmacol. Biol. Psychiatry, 30, 1381-1393.